Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05387811 · ClinicalTrials.gov registry record
International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
A clinical trial of Acute Kidney Injury and Liver Cirrhosis, sponsored by Azienda Ospedaliera di Padova.
- Completed
- Registry status
- 1,456
- Enrollment target
- 20
- Study locations
NCT05387811 is a study of Acute Kidney Injury and Liver Cirrhosis that has completed, run by Azienda Ospedaliera di Padova. The registered enrollment target is 1,456 participants, below the 2,311-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05387811, a study of Acute Kidney Injury and Liver Cirrhosis, has completed, sponsored by Azienda Ospedaliera di Padova.
- COMPLETED
- Registry status
- 1,456 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aims of this study will be to identify the clinical characteristics, the management and the outcomes of acute kidney injury in patients with cirrhosis worldwide. Specific aims: 1. To establish the severity of AKI across different regions 2. To identify precipitants of AKI across different centers 3. To identify the phenotypes of AKI across different centers 4. To evaluate differences in the management of AKI across different centers and their impact on clinical outcomes 5. To assess outcomes of acute kidney injury (resolution of AKI, in-hospital mortality, 28-day mortality, 90-day mortality)
Conditions Studied
Interventions
- COMBINATION_PRODUCT Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Study Locations (20)
Other
- Hospital de Gastroenterología "Dr. Carlos Bonorino Udaondo" - Buenos Aires
- Hospital Italiano - Buenos Aires
- Hospital Nacional Prof. Alejandro Posadas - El Palomar
- Universidad de Rosario - Rosario
- Hospital Federal de Bonsoccesso - Rio de Janeiro
- Universidad de Chile - Santiago
- Shanghai Jiao Tong University School of Medicine - Shanghai
- Hvidovre Hospital - Copenhagen
- Ain Shams University - Cairo
- Black Lion Hospital - Addis Ababa
- Jean Minjoz University Hospital - Besançon
- Hospital Beaujon - Clichy
- University of Aachen - Aachen
- University Hospital Munich - Munich
- Hospital of Debrecen - Debrecen
Indiana
- Indiana University - Indianapolis
Louisiana
- Ochsner Medical Center - New Orleans
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- Baylor University Medical Center - Dallas
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,456 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2023-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05387811
The ClinicalTrials.gov registry entry for NCT05387811 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,456 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,311-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (37% lower). The listed sponsor is Azienda Ospedaliera di Padova, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 1 intervention - of which Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy is the first listed.
NCT05387811 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Indiana, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05387811 about?
NCT05387811 is a clinical study titled "International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project". The aims of this study will be to identify the clinical characteristics, the management and the outcomes of acute kidney injury in patients with cirrhosis worldwide. Specific aims: 1. To establish the severity of AKI across different regions 2. To identify precipitants of AKI across different cent...
What is the current status of trial NCT05387811?
This trial is currently completed. The enrollment target is 1,456 participants. The study started on 2022-07-01. Estimated completion is 2023-11-30.
What conditions does trial NCT05387811 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Liver Cirrhosis, Hepatorenal Syndrome.
What interventions are being tested in trial NCT05387811?
The interventions under investigation include: Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05387811?
This trial is sponsored by Azienda Ospedaliera di Padova, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05387811 being conducted?
This trial has 20 study locations across Indiana, Louisiana, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
-
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.